logo
  

Lexmark International Q3 Profit Up; Revises FY14 Outlook

Laser printer manufacturer Lexmark International, Inc. (LXK) Tuesday reported its third-quarter earnings of $38 million or $0.60 per share, up from $34 million or $0.53 per share last year.

Excluding certain items, the company earned $1.05 per share for the quarter.

On average, 7 analysts polled by Thomson-Reuters estimated the company's earnings to be $0.92 for the quarter. Analysts' estimates typically exclude one-time items.

Quarterly revenues improved to $918 million from $890 million a year ago. Analysts were looking for revenues of $889.62 million.

Looking forward, for the fourth quarter, the company expects earnings per share in the range of $0.56 - $0.66. On an adjusted basis, earnings are expected to be around $1.10 - $1.20. Also, total revenue is currently expected to be down 2 to 4 percent. Analysts estimate earnings per share of $1.18, on revenues of $972.29 million.

For the fiscal 2014, the group sees earnings per share in the range of $2.21 - $2.31, while on an adjusted basis, earnings are projected to be around $4.05 - $4.15, an increase to the mid-point of the previous guidance of $3.95 - $4.15.

Revenue is currently expected to be in the range of flat to down 1 percent, an increase to the mid-point of the previous guidance of flat to down 2 percent. Analysts forecast earnings per share of $4.00 per share, on revenues of $3.64 billion.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT